Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression

International Journal of Cancer

Volumn 105, Issue 3, 2003, Pages 326-330

  Dowen, S E ^a   Scott, A ^b   Mukherjee, G ^c   Stanley, M A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

Carcinoma of the cervix; HPV; p27; Skp2

Indexed keywords

CELL PROTEIN; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL NUCLEUS; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME BINDING; ENZYME SUBSTRATE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN TARGETING; TUMOR DIFFERENTIATION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX EPITHELIUM; WART VIRUS;

CELL CYCLE; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL NUCLEUS; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); S-PHASE KINASE-ASSOCIATED PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 0038219965     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11066     Document Type: Article

References (32)

1. Demetrick DJ, Zhang H, Beach DH. Chromosomal mapping of the genes for the human CDK2/cyclin A-associated proteins p19 (SKP1A and SKP1B) and p45 (SKP2). Cytogenet Cell Genet 1996;73:104-7.
2. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-9.
3. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, Krek W. p45SKP2 promotes p27Kip1 degradation and induces S-phase in quiescent cells. Nat Cell Biol 1999;1:207-14.
4. Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, Shirane M, Tsunematsu R, Tsukiyama T, Ishida N, Kitagawa M, Hatakeyama S. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 2000;19:2069-81.
5. Marti A, Wirbelauer C, Scheffner M, Krek W. Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1999;1:14-9.
6. Yu ZK, Gervais JL, Zhang H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci USA 1998;95:11324-9.
7. Carrano AC, Pagano M. Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression. J Cell Biol 2001;153:1381-90.
8. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183:10-7.
9. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001;98:5043-8.
10. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T. High expression of S-phase kinase-interacting protein 2. human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001;61:7044-7.
11. Latres E, Chiarle R, Schulman BA, Pavletich NP, Pellicer A, Inghirami G, Pagano M. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA 2001;98:2515-20.
12. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K, Mori M. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 2002;62:3819-25.
13. Yokoi S, Yasui K, Saito-Ohara F, Koshikawa K, Iizasa T, Fujisawa T, Terasaki T, Horii A, Takahashi T, Hirohashi S, Inazawa J. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002;161:207-16.
14. Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Durr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996;13:2323-30.
15. Milde-Langosch K, Riethdorf S, Kraus-Poppinghaus A, Riethdorf L, Loning T. Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1 and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch 2001;439:55-61.
16. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
17. International Agency for Research on Cancer. 1ARC Monographs on the Evaluation of Carcinogenic Risks to Humans 1995;74.
18. Heselmeyer K. Macville M, Schrock E, Blegen H, Hellstrom AC, Shah K, Auer G, Ried T. Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer 1997;19:233-40.
19. Kirchhoff M, Rose H, Petersen BL, Maahr J, Gerdes T, Lundsteen C, Bryndorf T, Kryger BN, Christensen L, Engelholm SA, Philip J. Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-stage cervical carcinoma. Genes Chromosomes Cancer 1999;24:144-50.
20. Matthews CP, Shera KA, McDougall JK. Genomic changes and HPV type in cervical carcinoma. Proc Soc Exp Biol Med 2000;223:316-21.
21. Ried T, Heselmeyer-Haddad K, Blegen H, Schrock E, Auer G. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumours: a phenotype/genotype correlation. Genes Chromosomes Cancer 1999;25:195-204.
22. Mitelman F, Johansson B, Mandahl N, Mertens F. Clinical significance of cytogenetic findings in solid tumors. Cancer Genet Cytogenet 1997;95:1-8.
23. Rodriguez E, Sreekantaiah C, Chaganti RS. Genetic changes in epithelial solid neoplasia. Cancer Res 1994;54:3398-406.
24. Babu VR, Lutz MD, Miles BJ, Farah RN, Weiss L, Van Dyke DL. Tumour behaviour in transitional cell carcinoma of the bladder in relation to chromosomal markers and histopathology. Cancer Res 1987;47:6800-5.
25. Jin C, Jin Y, Wennerberg J, Dictor M, Mertens F. Non-random pattern of cytogenetic abnormalities in squamous cell carcinoma of the larynx. Genes Chromosomes Cancer 2000;28:66-76.
26. Chiarle R, Fan Y, Piva R, Boggino H, Skolnik J, Novero D, Palestro G, De Wolf-Peeters C, Chilosi M, Pagano M, Inghirami G. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S-phase. Am J Pathol 2002;160:1457-66.
27. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002;110:633-41.
28. Ganiatsas S, Dow R, Thompson A, Schulman B, Germain D. A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT. Oncogene 2001;20:3641-50.
29. Patton EE, Willems AR, Tyers M. Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis. Trends Genet 1998;14:236-43.
30. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999;15:435-67.
31. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999;9:661-4.
32. Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakides TR, Roberts JM, Kyriakidis TR. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S-phase. Nature 2001;413:323-7.